1426214-59-6

Basic information

• Product Name: 2,5-dichloro-N-[2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]benzenesulfonamide
• Synonyms: 2,5-dichloro-N-[2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]benzenesulfonamide
• CAS NO: 1426214-59-6
• Molecular Weight: 446.135
• Mol File: 1426214-59-6.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 2,5-dichloro-N-[2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]benzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2,5-dichloro-N-[2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]benzenesulfonamide(1426214-59-6)
• EPA Substance Registry System: 2,5-dichloro-N-[2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]benzenesulfonamide(1426214-59-6)

Safety Data

• Hazardous Substances Data: 1426214-59-6(Hazardous Substances Data)

Upstream product

• 5402-73-3 2,5-dichlorobenzenesulphonyl chloride 
• 819058-34-9 2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline 

Downstream Products

• 1426214-60-9 2,5-dichloro-N-[4-(6-chloro-5-formyl-pyrazin-2-yl)-2-fluoro-phenyl]benzenesulfonamide 

Relevant articles and documents

Discovery of N-[4-(1H-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides as highly active and selective SGK1 inhibitors

From a virtual screening starting point, inhibitors of the serum and glucocorticoid regulated kinase 1 were developed through a combination of classical medicinal chemistry and library approaches. This resulted in highly active small molecules with nanomolar activity and a good overall in vitro and ADME profile. Furthermore, the compounds exhibited unusually high kinase and off-target selectivity due to their rigid structure. (Chemical Presented).

N-[ 4-(1H-pypazolo [3, 4-b] aminopyrazine-6-yl)-phenyl]-and its use as a chemical acylsulfonamide

PROBLEM TO BE SOLVED: To provide a compound effective for the treatment of diseases due to the inadequacy of serum and glucocorticoid adjustment kinase (SGK) activities, for instance, degenerative arthropathy or inflammatory process, e.g., osteoarthritis or rheumatism, to provide its use as a drug, and to provide a pharmaceutical composition containing the same. SOLUTION: The compound is represented by formula I ( wherein, Ar is selected from the group consisting of phenyl and five- or six-membered monocyclic aromatic heterocyclic rings each containing a ring heteroatom selected from the group consisting of nitrogen, oxygen and sulfur; R1 is H, amino or the like; R2 is a halogen atom, alkyl or the like; and n is 0, 1 or 2). COPYRIGHT: (C)2013,JPOandINPIT

N-[4-(1H-PYRAZOLO[3,4-B]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS

The present invention relates to N-[4-(1H-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides of the formula (I), (R2)n wherein Ar, R1, R2 and n have the meanings indicated in the claims. The compounds of the formula (I) are valuable pharmacologically active compounds which modulate protein kinase activity, specifically the activity of serum and glucocorticoid regulated kinase (SGK), in particular of serum and glucocorticoid regulated kinase isoform 1 (SGK-1, SGK1), and are suitable for the treatment of diseases in which SGK activity is inappropriate, for example degenerative joint disorders or inflammatory processes such as osteoarthritis or rheumatism. The invention furthermore relates to processes for the preparation of the compounds of the formula (I), their use as pharmaceuticals, and pharmaceutical compositions comprising them.